We believe that testing whether ADAM10 is activated by TRP channels under physiological conditions is worthwhile, in addition to determining whether targeting TRP channels to activate ADAM10 is potentially useful for the treatment of AD. This evidence concerns the gene ADAM10 and Alzheimer disease.